The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases

Table 2

Number of guidelines reviewed by geographic region.

Disease area	US guidelines	EU guidelines	Global guidelines	Total
IHD	3	3	0	6
NSCLC	7	12	0	19
COPD	4	1	19	24
AD	4	3	0	7
T2D	29	5	2	36
Total	47	24	21	92

IHD = ischemic heart disease; NSCLC = non-small cell lung cancer; COPD = chronic obstructive pulmonary disease; AD = Alzheimer’s disease; T2D = type 2 diabetes.